New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), used to treat diabetes and obesity, may also be repurposed for opioid use disorder (OUD) and...
Top line: In the treatment of weight relapse after metabolic bariatric surgery (MBS), semaglutide 1.0 mg/week produced greater weight loss than liraglutide 3.0 mg/day. methodology: This...
2022 Guideline Update Released by KDIGO Organization for Managing People with Diabetes chronic kidney disease (CKD) highlighted the safety and extended evidence-based roles of three drug...
The US Food and Drug Administration (FDA) has approved a weekly 2.4 mg subcutaneous dose of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy, Novo Nordisk)...
Recent Comments